Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,524 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 6,524 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $18.65, for a total value of $121,672.60. Following the sale, the director directly owned 393,147 shares of the company’s stock, valued at $7,332,191.55. The trade was a 1.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Maplight Therapeutics Trading Down 4.8%

Maplight Therapeutics stock traded down $0.89 during mid-day trading on Friday, reaching $17.69. The company had a trading volume of 259,632 shares, compared to its average volume of 186,272. Maplight Therapeutics, Inc. has a 52 week low of $12.24 and a 52 week high of $21.55. The stock has a market cap of $802.60 million and a price-to-earnings ratio of -0.48. The stock’s 50 day simple moving average is $17.62.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Morgan Stanley initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price for the company. Leerink Partners initiated coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price target for the company. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Stifel Nicolaus assumed coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 target price on the stock. Finally, Weiss Ratings began coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They set a “sell (e)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.